EUCTR2004-000996-33-DK进行中（未招募）1 期
A global phase IV, double-blind, placebo-controlled, randomized trial to evaluate the effectiveness of Detrusitol SR 4 mg on Patient's Perception of Bladder Condition (PPBC). - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer ApS
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects to be included in the study are those:
- •1. who are outpatients > 18 years of age.
- •2. with self-reported symptoms of OAB for ³ 3 months prior to Visit 1 (screening).
- •3. who have OAB as defined by urinary frequency a minimum of 8 micturitions per 24 hours, as confirmed by the diary.
- •4. who have urgency (defined as a strong and sudden desire to urinate) with at least 3 episodes in 3 days urge incontinence, as confirmed by the micturition bladder diary between Visit 1 (screening) and Visit 2 (baseline).
- •5. who describe the degree of bothersomeness of their most bothersome OAB symptom as moderately or more, a great deal ”, or a very great deal” per the OAB Bother Rating Scale.
- •6. who have had a urinalysis negative for evidence of infection or hematuria within the past 3 months.
- •7. able and willing to attend all clinic visits.
- •8. able and willing to complete all micturition diaries and study questionnaires.
- •9. able to visit the toilet without assistance.
- •10. capable of understanding the research nature of the treatment and the risk of adverse events, and having signed the informed consent form after full discussion and prior to the initiation of any study related procedures.
- •11. able, in the opinion of the investigator, to read and follow written instructions and to comply with the requirement of the clinical trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects to be excluded are those:
- •1. who responded my bladder condition does not cause me any problems at all” on the Patient’s Perception Bladder Condition questionnaire at baseline.
- •2. with any condition that would contraindicate their usage of Detrusitol SR 4mg once daily (OD), including: narrow angle glaucoma, urinary retention, gastric retention.
- •3. with an allergic reaction or hypersensitivity to Detrusitol.
- •4. who have, in the judgment of the investigator, any clinically significant local urinary tract pathology which could mimic the symptoms of OAB, such as infection or hematuria.
- •5. with stress incontinence, functional, or overflow incontinence as determined by the investigator.
- •6. with symptomatic acute urinary tract infection (UTI) during the screening period, or recurrent urinary tract infections defined by treatment for symptomatic UTI > 3 times in the 12 months prior to participation in this clinical trial.
- •7. with clinically significant urinary tract obstruction.
- •8. with history of lower urinary tract surgery (e.g. prostate removal or destruction, incontinence surgery) within the past 3 months.
- •9. with clinically significant interstitial cystitis or significant bladder pain syndrome.
- •10. males with a history of prostate carcinoma treated with external or interstitial radiation, radioactive seeds, or a radical prostatectomy.
- •11. females with a history of uterine, cervical, vulvar, or vaginal carcinoma treated with external or interstitial radiation.
- •12. females who have had a radical hysterectomy.
- •13. females who have pelvic organ prolapse protruding through the introitus at rest in the supine position.
- •14. with unstable diabetes mellitus in the judgment of the investigator.
- •15. with spinal cord injury or multiple sclerosis.
- •16. who have less than 3 bowel movements per week.
- •17. with indwelling catheter or practicing intermittent self-catheterization.
- •18. with a history of or documented hepatic or renal dysfunction, defined as serum transaminases, blood urea nitrogen (BUN) or creatinine, greater than twice the upper limit of normal for the laboratory within the past 6 months.
- •19. who are currently managed with anticholinergics for symptoms of OAB.
- •20. who have initiated estrogen treatment (topical or systemic) within 4 weeks prior to Visit 1 (screening).
- •21. treated within 14 days preceding the screening visit, or expected to start therapy during the study treatment period with:
- •- any drug successfully used to treat urinary urge incontinence.
- •- concomitant treatment with potent CYP3A4 inhibitors, such as macrolide antibiotics (erythromycin) or antifungal agents (ketoconazole).
- •22. requirement for intermittent use of diuretics.
- •23. on an unstable dosage of any drug with anticholinergic side effects within 14 days preceding the screening visit (Visit 1) or expected to start treatment during the trial.
- •24. who have started any electrostimulation, bladder training, or pelvic floor exercises (with certified incontinence practitioners) within 4 weeks of Visit 1.
- •25. previously included in this study or patients who have received an investigational drug within 30 days prior to study entry.
- •26. pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception. Oral contraceptive agent, intrauterine device (IUD), implantable contraceptive, or injectable contraceptive (must have been used for at least 2 months prior to entering the study and continue to use throughout the st
研究者
相似试验
进行中（未招募）
不适用
A global phase IV, double-blind, placebo-controlled, randomized trial to evaluate the effectiveness of Detrusitol SR 4 mg on Patient's Perception of Bladder Condition (PPBC). - N/AOveractive bladder syndrome (OAB)EUCTR2004-000996-33-SEPfizer AB600
进行中（未招募）
1 期
A global phase IV, double-blind, placebo-controlled, randomized trial to evaluate the effectiveness of Detrusitol SR 4 mg on Patient's Perception of Bladder Condition (PPBC). - N/AOveractive bladder syndrome (OAB)EUCTR2004-000996-33-GBPfizer Global Pharmaceuticals, Pfizer Inc.600
进行中（未招募）
不适用
A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC).Overactive bladder conditionMedDRA version: 6.1Level: SOCClassification code 10038359EUCTR2004-000996-33-ITPFIZER730
进行中（未招募）
不适用
Pancreatic enzyme replacement therapy (PERT) in subjects with pancreatic exocrine insufficiency (PEI) after acute necrotizing pancreatitisEUCTR2013-005310-35-ESFundación para la Investigación en Enfermedades del Aparato Digestivo
进行中（未招募）
1 期
Efficacy and safety of XAV-19 for the treatment of moderate COVID-19Moderate COVID-19MedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-005979-12-BGXENOTHERA870